Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 8, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Sean McKeague1, Joanna Katarzyna Czerwinski2, Xavier Badoux3

  • 1Department of Haematology and Bone Marrow Transplantation, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.

Internal Medicine Journal
|July 7, 2026
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

British journal of haematology·2026
Same author

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Nature reviews. Clinical oncology·2026
Same author

Frontline CLL: lessons from the final analysis of CLL13-GAIA.

Blood·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

Advances in therapy·2026
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026
Summary

This expert consensus provides updated guidance for chronic lymphocytic leukaemia (CLL) diagnosis and management in Australasia. It incorporates recent advances in targeted therapies and molecular diagnostics for improved patient care.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Practice Guidelines

Background:

  • A 2023 consensus statement on chronic lymphocytic leukaemia (CLL) diagnosis and management in Australasia was previously published.
  • Significant advances in clinical evidence, molecular diagnostics, and targeted therapies have since emerged.
  • These advancements necessitate an update to contemporary CLL management strategies.

Purpose of the Study:

  • To provide an expert consensus update to the 2023 statement.
  • To offer current, regionally relevant guidance on CLL diagnosis, risk stratification, and management.
  • To address treatment selection, therapy sequencing, complication management, and supportive care.

Main Methods:

  • Recommendations developed through a structured consensus process.
Keywords:
BCL2 inhibitorsBTK inhibitorsCLLChronic Lymphocytic LeukaemiaConsensus guidelineSmall lymphocytic lymphoma

Related Experiment Videos

Last Updated: Jul 8, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

  • Involvement of Australian and New Zealand clinicians with CLL expertise.
  • Endorsement by key Australasian hematology organizations.
  • Application of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for evidence and recommendations.

    • Main Results:

    • Updated guidance on the diagnosis and risk stratification of CLL.
    • Current recommendations for treatment selection and sequencing of therapy.
    • Strategies for managing complications and providing supportive care for CLL patients.
    • Incorporation of new molecular diagnostics and targeted therapies into management.

    Conclusions:

    • The updated consensus provides essential guidance for Australian and New Zealand clinicians managing CLL.
    • It reflects the latest evidence and therapeutic advancements in the field.
    • The recommendations aim to optimize patient outcomes through evidence-based, regionally relevant care.